Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2020 Aug 8;48(2):383–394. doi: 10.1007/s00259-020-04978-6

Fig. 4.

Fig. 4

[89Zr]ZrDFO-Amivantamab binding (Baseline) and blocking with 200-fold excess unlabeled Amivantamab (Amivantamab block), single arm α-EGFR (EGFR block), and single arm α-c-MET (c-MET block) in HCC827 (a) (n = 3 replicates each; *** p < 0.001, **** p < 0.0001)